EMA Recommends Extension of Indications for Ribociclib to Include Use in Patients with Early Breast Cancer By Ogkologos - November 5, 2024 762 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with early breast cancer at high risk of recurrence Source RELATED ARTICLESMORE FROM AUTHOR Enzalutamide Continues to Provide Substantial Long-Term OS Benefit at 8 Years for Patients with Metastatic Hormone-Sensitive Prostate Cancer Metastatic Breast Cancer: ESMO Living Guideline No Additional Benefit From Tiragolumab Plus Atezolizumab Over Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Fedratinib December 23, 2020 Immunotherapy’s Role in Treating Endometrial Cancer Expected to Grow April 12, 2023 FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma November 6, 2025 Here’s Why We’re Building Pet-Friendly Domestic Violence Shelters–And How You Can... October 18, 2021 Load more HOT NEWS Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced... The Gift of Time NHS England change of chief executive – what does it mean... FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR...
